title: [Cholestatic síndrome due to labetalol].
authors.forename: M
authors.initials: M
authors.lastname: Vicuña-Arregui
authors.forename: D
authors.initials: D
authors.lastname: Ruiz-Clavijo-García
authors.forename: J M
authors.initials: JM
authors.lastname: Zozaya-Urmeneta
authors.forename: F
authors.initials: F
authors.lastname: Bolado-Concejo
authors.forename: O
authors.initials: O
authors.lastname: Nantes-Castillejo
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D001017:Aortic Coarctation / Q000150:complications / Q000188:drug therapy; D001778:Blood Coagulation Disorders / Q000139:chemically induced / Q000150:complications; D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology*; D002779:Cholestasis / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D007741:Labetalol / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male
chemical_list: D000319:Adrenergic beta-Antagonists; D007741:Labetalol